SUMO 2/3 Antibody [SM23/496]
| Code | Size | Price |
|---|
| PSI-33-204-100ug | 100ug | £765.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1, kappa
Antibody Clonality: Monoclonal
Antibody Clone: SM23/496
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Shipping:
blue ice
Storage:
Aliquot and Store at -20C. Avoid freez-thaw cycles.
Documents
Further Information
Additional Names:
SUMO2/3 Antibody: HSMT3, SMT3B, SUMO3, Smt3A, SMT3H2, SMT3A, Small ubiquitin-related modifier 2, HSMT3, SUMO-2
Application Note:
Flow Cytometry: 0.5-1 ug/million cells
IF: 0.5-1 ug/ml
WB: 0.5-1 ug/ml
IHC (FFPE): 0.5-1 ug/ml for 30 minutes at RT (1)
Prediluted format : incubate for 30 min at RT (2)
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the SUMO2/3 antibody to be titered up or down for optimal performance.
IF: 0.5-1 ug/ml
WB: 0.5-1 ug/ml
IHC (FFPE): 0.5-1 ug/ml for 30 minutes at RT (1)
Prediluted format : incubate for 30 min at RT (2)
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the SUMO2/3 antibody to be titered up or down for optimal performance.
1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Background:
This antibody reacts with both SUMO2 and SUMO3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1/2/3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several targets, which include MDM2, p53, PML and RanGap1. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer?s disease.
Buffer:
PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration:
0.2 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Recombinant human SUMO2 protein was used as the immunogen for this SUMO2/3 antibody.
NCBI Gene ID #:
6613
NCBI Official Name:
SMT3 suppressor of mif two 3 homolog 2 (S. cerevisiae)
NCBI Official Symbol:
SUMO2
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Purification:
Protein G purified
Research Area:
Homeostasis
Swissprot #:
P55854
User NOte:
Optimal dilutions for each application to be determined by the researcher